K. V. N. Naik S. P. Sanstha’s, Institute of Pharmaceutical Education & Research, Canada Corner, Nashik, 422002, Maharashtra, India.
Sustained-release (SR) tablet formulations signify a significant advancement in pharmaceutical therapy, allowing for steady therapeutic effects through controlled drug release over longer durations. This thorough review compiles the existing insights on the development, manufacturing, quality assessment, and clinical uses of SR tablets. SR systems sustain therapeutic drug levels between the minimum effective and maximum safe thresholds, avoiding the typical peak-and-valley plasma concentrations associated with standard immediate-release products, which helps to lower toxicity, reduce side effects, enhance patient compliance, and cut down the dosing frequency from three or four times a day to just once or twice daily. This review examines the key release mechanisms that influence SR tablet performance, such as diffusion-controlled systems that adhere to Fick's law and Higuchi kinetics, dissolution-based reservoir systems, polymer degradation processes in hydrophilic matrices, osmotic pump technology (OROS), and ion-exchange resin systems. Various classification systems are assessed, including matrix-based, reservoir-based, osmotic pump, coating-based, hybrid multilayer, gastroprotective, and microencapsulated multiparticulate technologies. The review scrutinizes different manufacturing methods including direct compression, wet granulation, dry granulation, hot-melt extrusion, and novel 3D printing techniques for their role in developing SR formulations. Detailed evaluation standards that include weight variation, hardness, friability, content uniformity, thickness measurements, and in vitro dissolution testing are outlined according to pharmacopeial guidelines. Key formulation obstacles, such as preventing dose dumping, optimizing bioavailability, and meeting regulatory standards, are discussed. Clinical uses of SR technologies across cardiovascular, endocrine, gastrointestinal, psychiatric, and respiratory ailments highlight their therapeutic value. This review presents a modern and integrated view of SR tablet science, establishing these systems as crucial therapeutic options for enhancing clinical outcomes in managing chronic diseases.
The creation of sustained-release drug delivery systems marks a significant milestone in the field of pharmaceutical science. Prior to the 1950s, medications were primarily designed as immediate-release forms that discharged drugs right away upon contact with water, lacking any mechanism for controlling the rate of release. This fundamental constraint changed significantly in 1952 when Smith Klein Beecham introduced the innovative Spansule technology, heralding the arrival of modern controlled drug delivery. The timeframe from 1950 to 1980 represented the first wave of development, during which four primary drug release mechanisms were identified and thoroughly investigated. Today, dissolution-controlled and diffusion-controlled systems continue to be the predominant technologies in FDA-approved formulations, with oral sustained-release formulations thriving due to their greater convenience and cost-effectiveness compared to other methods of administration1,2,3.
Sustained-release (SR) drug delivery systems are formulations specifically created to offer extended therapeutic benefits by continuously releasing medication over a prolonged time after a single dose is administered. In contrast to immediate-release formulations that result in rapid drug absorption and immediate therapeutic responses, SR systems achieve consistent and predetermined rates of drug delivery, ideally resembling zero-order kinetics, independent of the drug concentration in the dosage form(Figure 1). The fundamental concept focuses on keeping therapeutic drug levels in the bloodstream between the minimum effective concentration and maximum safe concentration without the oscillating "peak and valley" profiles typical of standard formulations. This is especially beneficial for medications with short biological half-lives of 3–4 hours, for which traditional multiple-dose schedules would be challenging or could cause undesirable fluctuations in plasma concentrations. SR systems incorporate a variety of technological methods, including matrix-based systems (where drugs are integrated within hydrophilic or hydrophobic polymer matrices), reservoir systems (comprised of a drug core enclosed by semipermeable membranes), and osmotic pump systems (which use osmotic pressure gradients to facilitate constant drug delivery)4,5.
Figure 1: Plasma Concentration Profiles for Different Drug Release Systems
Advantages Of Sustained Release Dosage Forms:
Disadvantages Of Conventional Dosage Forms:
Fundamental Release Mechanisms of SR Tablets:
Diffusion-Controlled Release:
In diffusion systems, medications are incorporated into insoluble matrices and gradually diffuse through the matrix substance in accordance with Fick's law of diffusion. The rate at which the drug is released is influenced by the diffusion coefficient, the surface area, and the concentration gradient. Generally, these systems adhere to Higuchi kinetics and exhibit a high degree of predictability8.
Dissolution-Controlled Release:
The release of the drug is regulated by modifying the thickness of the coating (reservoir systems) or the rate at which the matrix dissolves (matrix systems). Increasing the coating thickness reduces the release speed, whereas the dissolution of the matrix determines the rate of drug availability9.
Erosion and Diffusion-Erosion Mechanisms:
Polymer erosion refers to the gradual breakdown of the matrix material, leading to the release of encapsulated drugs. Hydrophilic gel matrices, such as those made with HPMC, CMC, or xanthan gum, utilize a combination of diffusion and erosion processes. When water infiltrates the tablet, it creates a thick gel layer that regulates the diffusion of the drug, while the outer surface erodes simultaneously. This results in non-Fickian release kinetics characterized by exponents ranging from 0.5 to 1.010.
Osmotic-Controlled Release:
Osmotic pump systems utilize a semipermeable membrane coating and osmogenic agents to generate osmotic pressure, which pushes water into the core of the tablet. This internal pressure expels a drug solution through a laser-created orifice at a controlled, zero-order rate that is unaffected by pH and the properties of the drug. Controlled porosity osmotic pumps (CPOP) implement water-soluble pore-formers in place of laser drilling11.
Ion-Exchange Resin Systems:
Ion-exchange resins are insoluble polymers containing ionizable groups that can reversible attach to ionic medications. The release of the drug happens via ion-exchange when physiological counter-ions (such as Na?, K?, Cl?) compete with the medication for the binding sites on the resin. Factors such as the size of the resin particles, the degree of crosslinking, the amount of drug loaded, and the presence of polymer coatings all play a role in controlling the release rates12.
Film-Coated and Enteric-Coated Systems:
Enteric coatings utilize pH-sensitive polymers that do not dissolve in the acidic environment of the stomach but break down in the neutral or alkaline conditions found in the small intestine. This safeguards acid-sensitive medications and aims for targeted release within the intestines. Standard film coatings offer controlled dissolution by varying the thickness of the coating13
Kinetic Profiles:
The majority of sustained release (SR) systems target zero-order (constant rate) kinetics, wherein a steady quantity of the drug is released over time. This is different from immediate-release formulations that demonstrate first-order kinetics with progressively decreasing release rates. Osmotic systems can accomplish genuine zero-order kinetics, whereas hydrophilic matrix systems frequently approach zero-order behaviour through a combination of diffusion and erosion mechanisms14.
CLASSIFICATION SYSTEMS OF SUSTAINED-RELEASE TABLETS: CONCISE OVERVIEW:
1. Matrix-Based Systems:
Hydrophilic Matrices: Most common SR technology; swellable polymers (HPMC, sodium alginate, guar gum, xanthan gum, carbomer) hydrate to form gel layers controlling diffusion and erosion. Gel thickness is critical; thicker layers slow release. Soluble drugs show burst release; insoluble drugs release via erosion15.
Hydrophobic Matrices: Water-insoluble polymers (ethylcellulose, polyethylene, waxes) enable purely diffusion-controlled release with predictable kinetics but reduced flexibility16.
2. Reservoir-Based (Membrane-Controlled) Systems:
Drug core enclosed in rate-controlling polymeric membrane via press-coating or encapsulation. Maintains uniform thickness enabling zero-order kinetics and preventing dose dumping. Porous membranes allow aqueous penetration through tortuous pathways; non-porous membranes control purely through polymer diffusivity (Figure 2).
Advantages: Zero-order kinetics, dose-dumping prevention, tunable release.
Disadvantages: Complex manufacturing, potential rupture, difficulty with degradable systems.
Figure 2: Dissolution-Controlled Drug Release Mechanisms in Reservoir and Matrix Systems17
3. Osmotic Pump Tablets:
Exploit osmotic pressure for zero-order release independent of pH/GI motility18.
Advantages: Consistent zero-order kinetics, pH/GI independence, minimal dose dumping. Limitations: Complex manufacturing, high cost, GI irritation potential, regulatory complexity18.
4. Coating-Based (Membrane-Coated) Systems:
Enteric-Coated: pH-sensitive polymers (Eudragit L, S, FS) remain intact at gastric pH, dissolve at intestinal pH; site-specific, not true SR23.
Sustained-Release Coated: Slowly dissolving coatings progressively release drug through GI transit24.
Microporous/Porous: Interconnected pores allow aqueous diffusion through tortuous pathways; achieves zero-order kinetics with reduced complexity25.
5. Hybrid and Advanced Systems:
Multilayer Tablets: Multiple functional layers enable biphasic delivery or incompatible API separation; modulated barriers enable zero-order release.
Microencapsulated Multiparticulates: Drug-containing microspheres (1–1000 μm) individually provide SR; combined effect produces overall SR profiles. Materials: PLGA, PLA (biodegradable), Eudragit, cellulose derivatives, lipids. Advantages: Customizable morphology, flexible drug loading, blendable for complex patterns. Challenge: Compaction damage reduces coating effectiveness; ≥50 μm coatings resist compression better26.
Micro-Reservoir Systems: Drug suspended in aqueous polymer, dispersed throughout lipophilic matrix forming microscopic reservoirs; achieves zero-order kinetics27.
6. Gastroretentive Systems:
Floating Tablets: Tablets that generate gas (CO?) and are low-density, combined with hydrophilic polymers (HPMC, PEO), can stay afloat for 8 to 12 hours, which prolongs their stay in the stomach. Benefits include extended delivery in the upper gastrointestinal tract and enhanced bioavailability for drugs that are absorbed in specific sites. However, their effectiveness is influenced by the fullness of the stomach, and the transit time can vary28.
Floating-Bioadhesive Tablets (FBS): Incorporate bioadhesive polymers (CMC, HPMC) to enhance adhesion to mucosal surfaces; prolong retention for over 5 hours; improve bioavailability by 1.7 times compared to immediate-release formulations28.
7. Ion Exchange Resin-Based Tablets:
Water-insoluble polymers that resist water and contain ionizable groups can exchange counter-ions in gastrointestinal fluids, leading to a gradual drug release.
Benefits include prevention of dose dumping, consistent release, and diminished burst effect. However, there are drawbacks such as complicated formulations, the requirement for ionizable drugs, and dependency on gastrointestinal ion concentration29.
Polymers and Excipients in Sustained-Release Tablets:
1. Hydrophilic Polymers (Swellable/Gel-Forming):
HPMC (Hydroxypropyl Methylcellulose) is the most commonly utilized hydrophilic polymer; it dissolves in water and generates clear, viscous gels when hydrated in gastrointestinal fluids. It maintains stability over a pH range of 3–11 and comes in various viscosity grades (K4M, K15M, K100LV) that can be used to adjust release rates. Higher viscosity grades lead to slower drug release due to the formation of thicker gel layers; the degree of hydroxypropyl substitution is directly related to the rate of hydration and the release of the drug30.
Sodium CMC (Carboxymethyl Cellulose): It is an anionic, polymer that dissolves quickly in cold water and exhibits a high degree of hydrophilicity, with the ability to absorb over 50% of its weight in water. It creates robust films that resist oils and greases, remains stable across a range of pH levels, and is often combined with HPMC to improve gel strength and facilitate pH-independent release30.
Carbomer (Polyacrylic Acid) exhibits a significant ability to swell; its solubility is dependent on pH and needs to be neutralized; it creates robust, inflexible gels by forming hydrogen bonds with HPMC; it enhances viscosity and regulates diffusion; it is restricted to environments with acidic to neutral pH levels31.
2. Hydrophobic Polymers (Non-Swelling):
Ethyl Cellulose (EC) is insoluble in water and allows for release that is controlled by diffusion through complex pathways. It provides a reliable, non-swelling method for sustained release and exhibits good chemical stability. It works well with plasticizers such as PEG and triethyl citrate, but has less flexibility in manufacturing. EC is often used alongside HPMC to create hybrid systems that combine hydrophobic and hydrophilic properties32.
Polyethylene and waxes are non-swelling polymers that absorb very little water; they provide sustained release solely through the diffusion of drugs; they exhibit high resistance to erosion; they are primarily effective for lipophilic drugs; their application is restricted because of the excretion of residual matrix33.
3. pH-Dependent Polymers:
pH-sensitive polymers are unique materials utilized in sustained-release tablets to direct drug delivery to specific areas of the gastrointestinal tract. These polymers, including methacrylic acid copolymers (Eudragit L100 and S100), remain insoluble in the acidic environment of the stomach but dissolve at higher pH levels found in the intestine (usually pH 5–7)34. This characteristic allows tablets to travel through the stomach without disintegrating and to release the medication gradually in the small intestine, often employing coatings that create channels or pores at the correct pH. These systems are frequently used for drugs that are sensitive to acid or require delivery in the intestine, enabling sustained and targeted drug release based on changes in the gastrointestinal environment35.
4. Natural Polymers/Gums:
Guar Gum: A natural polysaccharide derived from legume seeds; quickly absorbs water; forms strong gels; experiences slower degradation than HPMC; exhibits moderate swelling (74.6–108.9% at 6 hours); provides extended release for up to 24 hours; demonstrates Higuchi or anomalous diffusion kinetics depending on its concentration; is biocompatible, biodegradable, and cost-effective36.
Xanthan Gum: A polysaccharide produced through bacterial fermentation; creates strong gels; demonstrates remarkable swelling (85.2–120.5% at 6 hours); offers excellent sustained-release properties for up to 24 hours; maintains stability across a range of pH levels; works synergistically with guar or locust bean gum; the primary mechanism involves diffusion-erosion exhibiting non-Fickian kinetics37.
Sodium Alginate is a natural polysaccharide derived from brown seaweed; it hydrates quickly and has the ability to exchange ions (the M/G content ratio affects the release). When used alongside HPMC, it exhibits synergistic effects for a release that is independent of pH; it prevents an initial burst by quickly forming a gel. Additionally, it has improved biocompatibility and adherence to mucosal surfaces14.
Pectin is a natural polysaccharide that is biodegradable and can be degraded by colonic microbes, allowing for targeted delivery to the colon. It is more stable in the gastrointestinal tract compared to other natural gums. Pectin is particularly effective for targeted microparticle systems, resulting in reduced burst release and controlled delivery. While it is not suitable for traditional matrix tablets due to its fast breakdown in the upper gastrointestinal tract, it is highly valuable for applications aimed at the colon38.
Table 1: Excipients Used in Sustained Release Tablet Formulations and Their Functional Roles
|
Ingredient |
Typical Quantity (% w/w) |
Role |
|
Active Pharmaceutical Ingredient (API) |
20 - 60% |
Therapeutic agent |
|
Sustained Release Polymers (e.g., HPMC K4M, Ethyl cellulose, PVP) |
10 - 40% |
Controls drug release |
|
Diluents/Fillers (MCC, Lactose, Starch) |
20 - 50% |
Tablet bulk & compressibility |
|
Binders (usually for wet granulation, e.g., PVP K30) |
2 - 5% |
Granule formation |
|
Lubricants (Magnesium stearate) |
0.5 - 1.5% |
Prevents sticking during compression |
|
Glidants (Talc, Colloidal silicon dioxide) |
0.5 - 2% |
Improves powder flow |
|
Disintegrants (if any, e.g., Starch) |
0 - 5% |
Control disintegration |
Criteria To Be Met to Incorporate the Drug in Sustained Release Dosage Form:
Table 2: Physicochemical parameter for drug selection
|
Sr. No. |
Parameters |
Criteria |
|
1 |
Molecular size |
< 1000 Daltons |
|
2 |
Aqueous Solubility |
More than 0.1 mg/ml for pH 1 to pH 7.8 |
|
3 |
Apparent partition coefficient |
High |
|
4 |
Absorption mechanism |
Diffusion |
|
5 |
General absorbability from all GI segments |
Release should not be influenced by pH and enzyme |
MANUFACTURING TECHNOLOGIES FOR SUSTAINED-RELEASE TABLETS:
1. Direct Compression (DC):
Principle: Medications and excipients are compressed straight into tablets without any granulation beforehand. This is the most straightforward manufacturing process39 (Figure 3).
Benefits: Fewer processing steps required; lower costs, energy consumption, and time; appropriate for APIs sensitive to heat/moisture; decreased contamination risks; preserves API stability; compatible with simple coating processes40.
Drawbacks: Necessitates costly DC-grade excipients (silicified microcrystalline cellulose, sodium stearyl fumarate); inadequate powder flow leads to issues with weight and content uniformity; limited dilution capability restricts drug loading.
SR Applicability: Confined to straightforward hydrophobic matrix formulations; unsuitable for hydrophilic matrices (HPMC, alginate) because of inadequate flow and polymer bridging41.
2. Wet Granulation:
Most common SR tablet manufacturing approach; produces robust tablets with superior uniformity42.
High-shear granulation involves mechanical mixing combined with the addition of a liquid binder, resulting in the quick formation of dense granules. This method is perfect for controlled-release formulations using HPMC and is particularly effective for low-dose active pharmaceutical ingredients that need an even distribution of binder.
Fluidized-Bed Granulation: Particles treated with air flow and binder spray create uniform granule characteristics; drying occurs on-site; suitable for large-scale manufacturing; reliable quality across different batches42.
Twin-Screw Wet Granulation (TSWG): A new continuous method that combines blending, granulation, and drying in one process. It features a short residence time of 5 to 20 seconds, utilizes minimal water, offers excellent uniformity in active pharmaceutical ingredients (APIs), and preserves the HPMC release characteristics for up to 24 hours; this approach supports the implementation of Quality by Design (QbD). Benefits include effective mixing that promotes uniformity, which decreases content variation and segregation; the continuous nature of the process allows for real-time monitoring and integration of Process Analytical Technology (PAT); and it can be easily scaled up without the need for reformulation. However, it poses
Figure 3: challenges such as the need for fast-wetting binders (with PVP often being the preferred option) and demands specialized equipment along with adequate training43.
Process Flow Diagram of Tablet Compression Techniques44
3. Dry Granulation:
Roller compaction or slugging without liquid; moisture/heat-sensitive polymers preserved; energy-efficient.
Process: Powder compressed into sheets/slugs, then milled into granules through pressure-induced particle bonding without liquid binder. Eliminates drying step.
Advantages: Protects moisture/heat-sensitive polymers; energy-efficient; simpler equipment. Disadvantages: Generally lower tablet strength than wet granulation; less precise API distribution; inferior content uniformity43.
4. Hot-Melt Extrusion (HME):
Solvent-free, continuous technology heating drug and polymers to temperatures above glass transition (~2 min residence time)45.
SR Capability: Creates molecular-level solid dispersions with HPMC, Eudragit, or lipids; produces pellets, mini-tablets, or pre-shaped extrudes for compression; improves bioavailability through molecular dispersion46 (Figure 4).
Benefits: Single-step processing; free from solvents (eliminating residual solvents); easily scalable in a continuous manner; reduced contact with oxygen and moisture lowers the risk of API oxidation/hydrolysis; enhanced bioavailability for drugs that are poorly soluble; environmental advantage due to the absence of solvent emissions45.
Limitations: Elevated processing temperatures (100–250°C) are not suitable for thermolabile medications; the substantial energy input raises expenses; specialized machinery and skilled personnel are necessary; careful management of critical process parameters (temperature, screw speed, feed rate, die geometry) is crucial for ensuring quality. It is vital to confirm drug-polymer miscibility to avoid phase separation that can influence release kinetics46.
Commercial Applications: Increasingly used for poorly soluble drug formulations; enabling technology for complex release patterns and personalized dosing47.
challenges such as the need for fast-wetting binders (with PVP often being the preferred option) and demands specialized equipment along with adequate training43.
Figure 4: Schematic Representation of the Hot-Melt Extrusion (HME) Process48
5. 3D Printing:
Approved by the FDA for pharmaceuticals in August 2015; currently being tested on a commercial scale for SR tablets, but shows potential for personalized and combination treatments49.
Methods: Fused Deposition Modelling (FDM) a thermoplastic filament that is extruded in layers; Semi-Solid Extrusion (SSE) a paste-like formulation of drug and polymer that is extruded; Inkjet a liquid drug solution that is applied in several passes; Stereolithography a photopolymer solidified by UV light that contains a dissolved drug50.
SR Capabilities: Facilitates the creation of bi-layer, tri-layer, and intricate multi-compartment designs. The internal architecture (including porosity, channels, and density variations) is designed for immediate, sustained, or pulsatile release patterns. The shape of the tablet can be tailored to meet individual patient needs50.
Benefits: Quick prototyping without the need for redesigning equipment; customized dosing for each patient based on pharmacogenomics and weight; tailored combinations of multiple medications arranged spatially for optimal effect; enables unique release patterns that are usually impossible to achieve (such as pulsatile or programmed multiple-peak release); minimizes waste through accurate material placement49.
Challenges: Restricted to low-dose formulations (less than 100 mg); production is slow (taking minutes per tablet compared to seconds with conventional compression); achieving uniform high drug-loading is challenging; thermolabile drugs are susceptible to degradation from heat or extrusion; the regulatory framework for 3D-printed medications is still developing; it is prohibitively expensive for large-scale industrial production; there are few biocompatible polymers or excipients available that are suitable for printing50.
Current Applications: Primarily investigational in hospitals/clinics for personalized dosing; veterinary medicine; paediatric dose customization; combination therapy tablets51.
Future: It is improbable that it will supplant traditional manufacturing for mass production in the near future, but it could transform applications in personalized medicine52.
EVALUATION TESTS FOR SUSTAINED-RELEASE TABLETS:
Sustained-release tablets require thorough assessment tests to guarantee their quality and effectiveness.
Weight Variation assesses the consistency of tablet weight within a batch, which is vital for accurate dosing, particularly for low-dose medications. Each tablet is weighed separately, and the difference from the average weight must fall within the limits set by the pharmacopeia (USP permits a variation of ±5–10% based on the size of the tablet).?
Hardness Testing evaluates the mechanical strength of tablets by applying compression until they break, confirming that they can withstand the stresses of handling and storage. The optimal hardness level falls between 6 and 15 kg/cm²; tablets that are too soft may disintegrate too early, while those that are too hard can postpone drug release longer than intended53.
The Friability Test evaluates the toughness of tablets by exposing them to rotational wear and measuring any reduction in weight. Generally, an acceptable level of friability is considered to be less than 1%. Tablets that are highly friable may crumble or fracture, which can affect the consistency of dosing and the uniformity of release.
Content uniformity assesses the consistency of active ingredient levels across individual tablets, typically using HPLC or UV analysis. Pharmacopeial standards stipulate that the labelled content must be between 85–115%, with a low relative standard deviation (<6%) to guarantee therapeutic effectiveness54.
Thickness measurement verifies dimensional consistency, which influences tablet swallowing, compression force, and dissolution rates. Using callipers for measurement, variations must remain within ±5% of the target thickness to ensure consistent dosage and release.?
The assessments carried out during and following the manufacturing process are essential for ensuring that sustained-release tablets provide reliable, safe, and effective treatment55.
Table 3: Quality Control Tests for Sustained-Release Tablets
|
Test |
Principle |
Test Procedure |
Acceptance Criteria / Standards |
Pharmaceutical / SR Significance |
|
Weight Variation |
Ensures uniform drug content; evaluates formulation and compression consistency |
Weigh 20 tablets individually; calculate average weight and % deviation |
USP: ≤130 mg: ±10%; 130–324 mg: ±7.5%; >324 mg: ±5%; (Max 2 outside limit; none >2× limit) BP/IP: ≤80 mg: ±10%; 80–250 mg: ±7.5%; ≥250 mg: ±5% |
Ensures dose uniformity and bioavailability; critical for low-dose (<50 mg API) SR formulations. |
|
Hardness |
Measures tablet mechanical strength to resist breakage during handling and coating |
Place tablet between platens; apply force until fracture; record pressure (kg/cm² or kP) |
6–15 kg/cm² typical; <4 = fragile; >18 = overly hard, delayed release |
Ensures structural integrity; affects disintegration and release kinetics. |
|
Friability |
Assesses tablet resistance to mechanical wear during transportation/handling |
Weigh 20 tablets (~6 g); rotate for 100 revolutions (4 min); reweigh; calculate % weight loss |
USP/BP/EP: ≤1.0% (preferably <0.5% for coated tablets); fails if cracked/broken or >1% loss |
Indicates formulation robustness; excessive friability may affect matrix integrity and SR behavior. |
|
Content Uniformity |
Verifies consistent API distribution among tablets for dose accuracy and efficacy |
Assay 10 individual tablets (or 30 for comprehensive batch) |
USP: 85–115% of label claim; RSD <6%; FDA: mandatory for <50 mg API |
Ensures consistent drug release; poor uniformity can cause burst or lag release effects. |
|
Thickness |
Ensures dimensional consistency; affects mechanical strength and release profile |
Measure 10–20 tablets at 3–4 points each |
±5% of target thickness |
Correlates with compression force: thicker = softer (friable), thinner = harder (slower release). |
Challenges In Sustained-Release (Sr) Tablet Formulation Include:
Formulation Complexity: Selecting the right combination of polymers, excipients, and manufacturing parameters is difficult, as slight changes can significantly affect drug release. Complex formulation design and GI variability require extensive optimization and testing56.
Dose Dumping: There is a risk of rapid, uncontrolled drug release (dose dumping) due to formulation failure, alcohol intake, or mechanical damage especially with narrow therapeutic index drugs. FDA closely scrutinizes SR formulations for dose dumping, requiring robust prevention strategies (e.g., hydrophobic coatings, multi-unit systems)57.
Bioavailability Issues: Poor or variable drug absorption can result from site-specific absorption windows, first-pass metabolism, patient-specific GI conditions, and poor solubility. Rigorous in vitro–in vivo correlation (IVIVC) studies are needed to predict and optimize SR performance58.
Regulatory Hurdles: Gaining approval for SR products is more demanding than immediate-release forms due to the need for extensive dissolution, stability, IVIVC, and bioequivalence studies under multiple conditions. The approval process is lengthy and requires comprehensive quality documentation59.
Cost Implications: SR tablet development and production entail high costs due to specialized excipients, advanced equipment, and stringent quality control/testing. This can limit access in low-income markets and often leads to higher end-user prices57.
Applications:
Cardiovascular conditions: SR tablets provide antihypertensive drugs, anti-anginal agents, and medications for heart failure (such as ivabradine and beta-blockers) continuously for extended durations, enhancing management and decreasing the frequency of doses60.
Diabetes: Extended-release versions of metformin and other diabetes medications provide improved glycaemic control and a reduced likelihood of side effects by minimizing peak and trough fluctuations.
Pain management: Commonly, opioids, NSAIDs, and medications for neuropathic pain are available as sustained-release tablets to deliver relief for 12–24 hours, reducing the frequency of dosing and enhancing patient quality of life.
Gastrointestinal (GI) disorders: Sustained-release tablets for issues such as GERD, ulcerative colitis, or Crohn’s disease allow for prolonged localized action and a decrease in GI-related side effects.
Psychiatric conditions: Sustained-release formulations of antidepressants, antipsychotics, and mood stabilizers maintain more consistent plasma levels, improving efficacy and tolerability.
Respiratory disorders: Bronchodilators and other respiratory medications in sustained-release formats provide better symptom control and enhanced adherence for individuals with chronic asthma or COPD.
CONCLUSION:
Sustained-release tablets signify a crucial development in medical therapeutics, revolutionizing drug delivery since the launch of Spansule technology in 1952. Through intricate release mechanisms such as diffusion, dissolution, erosion, osmotic pumping, and ion-exchange, SR systems sustain therapeutic drug levels within ideal safety margins, preventing harmful peak-valley variations typical of traditional formulations.
The key benefits of SR tablets including less frequent dosing, reduced side effects, better patient compliance, lower overall medication requirements, and improved therapeutic results underline their clinical importance across cardiovascular, endocrine, gastrointestinal, psychiatric, and respiratory ailments. Manufacturing techniques that range from direct compression and wet granulation to innovative methods like three-dimensional printing provide adaptable options for optimizing formulations based on specific drug characteristics.
Strict quality control measures, such as dissolution assessments, uniformity of content, hardness evaluations, and friability analysis, ensure consistent safety and efficacy. Although there are challenges like the risk of dose dumping, regulatory complexities, and elevated development costs, SR formulations still set the benchmark in the management of chronic diseases. Future advancements in continuous manufacturing, cutting-edge polymers, and personalized drug delivery systems are likely to enhance SR tablet performance further, securing these formulations’ roles as crucial therapeutic resources for bettering clinical results and patient quality of life within global healthcare frameworks.
REFERENCES
Sharad Dhotre*, Ritesh Deshmukh, Dr. Kanchan Jagtap, A Comphrensive Overview of Formulation Advances and Challenges, Mechanism in Sustained Released Tablet Formulation, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 12, 2412-2428 https://doi.org/10.5281/zenodo.17936133
10.5281/zenodo.17936133
